https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50840 Wed 28 Feb 2024 16:33:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53765 Wed 28 Feb 2024 15:59:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45438 Wed 20 Mar 2024 15:45:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51001 Tue 15 Aug 2023 12:06:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47085 Tue 13 Dec 2022 16:35:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49460 1000 mg prednisolone-equivalent cumulatively are likely to have serious side effects and adverse outcomes. Patient perspectives emphasize the detrimental impacts of OCS-related side effects such as weight gain, insomnia, mood disturbances and skin changes. Improvements in asthma control and prevention of exacerbations can be achieved by improved inhaler technique, adherence to therapy, asthma education, smoking cessation, multidisciplinary review, optimized medications and other strategies. Recently, add-on therapies including novel biological agents and macrolide antibiotics have demonstrated reductions in OCS requirements. Harm reduction may also be achieved through identification and mitigation of predictable adverse effects. OCS stewardship should entail greater awareness of appropriate indications for OCS prescription, risk–benefits of OCS medications, side effects, effective add-on therapies and multidisciplinary review. If implemented, OCS stewardship can ensure that clinicians and patients with asthma are aware that OCS should not be used lightly, while providing reassurance that asthma can be controlled in most people without frequent use of OCS.]]> Thu 18 May 2023 12:40:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40118 Fri 22 Jul 2022 13:48:23 AEST ]]>